This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Young Investigators Award

November 2022 Br J Cardiol 2022;29:134–6

Highlights from the BCS Annual Conference 2022: 100 years in cardiology

Alexandra Abel

Abstract

100 years in cardiology Born in 1922 and originally known as “The Cardiac Club”, the British Cardiovascular Society (BCS) is the world’s oldest professional cardiac society. To celebrate “100 years in cardiology”, five centenary lectures were given at BCS 2022 by world-renowned speakers (… three of whom were called John): Professor John Camm (heart rhythm); Professor Barbara Casadei (cardiovascular research in the UK); Professor John McMurray: (heart failure); Professor John Deanfield (coronary artery disease); and Professor Catherine Otto (cardiac imaging). The centenary lectures charted the impressive evolution of cardiovascular

| Full text

December 2013 Br J Cardiol 2014;21:12–3 Online First

Highlights from HRC 2013

BJCardio Staff and others

Abstract

What’s in a name Last year’s meeting saw Heart Rhythm UK (HRUK) change its title to the British Heart Rhythm Society (BHRS). Explaining the change, BHRS President Elect Dr Nick Linker (South Tees Hospitals NHS Foundation Trust) said that this made things more flexible for the future, and will also avoid confusion with any other organisation using the abbreviation HRUK. Ectopy in low- and high-risk patients Angela Hall (James Cook University Hospital, Middlesbrough) When are palpitations benign and when do they signal high risk? This thorny issue was addressed by Mrs Angela Hall, Lead Cardiac Rhythm Management (CRM) Specialist Nurse (James

| Full text
News from the BSH 15th Annual Autumn Meeting

February 2013 Br J Cardiol 2013;20:18-9

News from the BSH 15th Annual Autumn Meeting

Abstract

Mineralocorticoid receptor antagonists Professor Faiez Zannad (Université de Lorraine, Nancy, France), the first of two guest lecturers, who has been an investigator in three major randomised controlled trials (RCT) of mineralocorticoid receptor antagonists (MRA) in heart failure,1-3 opened the first session. There was a particular focus on the recent EMPHASIS-HF trial,3 which recruited heart failure (HF) patients with left ventricular systolic dysfunction (ejection fraction [EF] ≤30%, or EF 30-35% with QRS duration >130 ms) and mild symptoms (New York Heart Association [NYHA] class II). Eplerenone treatment resulted in a 37% relative

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now